OTR3 focuses on high potential programs
including award winning key projects.
OTR3 focuses on key development projects with high potential, with the aim of exploiting the versatility of the RGTA® technology to provide to patients new healthcare products that really matter.
The following development programs, relying on the regenerating potential of RGTA® molecules, are just only a fraction of the technology’s potential, and are to date the closer to market.
The excellence and potential of OTR3’s Pipeline has been confirmed by awards and grants (H2020 SME Instrument, Medicen Label, ANR grant, INCA)
Stroke Management
Funding
Stroke management through RGTA®: SMR
Acute ischemic stroke
Funding
La thérapie matricielle pour l’ischémie cérébrale : une nouvelle opportunité pour protéger le tissu cérébral en souffrance et pour promouvoir sa régénération ?
ANR-15-CE18-0029 MAESTRO: https://anr.fr/Projet-ANR-15-CE18-0029
Acute ischemic stroke
Funding
A matrix therapy to optimize MSC-derived extracellular vesicles for brain protection and repair after ischemia
ANR-21-CE18-0029: https://anr.fr/Projet-ANR-21-CE18-0029
Publications
Brain protection after radiotherapy
Funding
Matrix Therapy against Radiotherapy-Induced Brain damage and Cognitive deficits (Brain-MATRiX)
Alzheimer’s disease and tauopathies
Publications
